BACKGROUND: Vaccinia virus (VV) membrane proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic antibodies. Human antibody responses to these proteins after VV vaccination have not been well characterized. METHODS: Pre- and postvaccination (day 26-30) serum specimens from 80 VV vaccine recipients were examined for immunoglobulin G antibodies specific for B5, A33, A27, and L1 by enzyme-linked immunosorbent assay (ELISA). Responses were compared between vaccinia-naive and previously vaccinated (nonnaive) recipients and between nonnaive recipients of undiluted or 1 : 10 diluted vaccine. RESULTS: VV vaccination elicited anti-A33 and anti-A27 antibodies in nearly all vaccinia-naive subjects (100% and 93%, respectively). Preexisting antibodies were commonly detected in nonnaive subjects (for anti-B5, 68%; for anti-A33, 59%; for anti-A27, 38%; and for anti-L1, 10%). Anti-B5 antibodies were strongly boosted by undiluted vaccine (geometric mean titer [GMT], 151 vs. 1010 for pre- vs. postvaccination; P<.001), whereas anti-L1 antibody responses were less robust (detection rate, 31%; GMT, 75) in nonnaive subjects. Diluted vaccine elicited antibody responses that were similar to those elicited by undiluted vaccine. CONCLUSIONS: Vaccination with VV elicits long-lived specific antibody responses directed against VV membrane proteins that vary by previous vaccination status but not with respect to 10-fold dilution of vaccine. B5, A33, and A27 should be considered for inclusion in future human orthopoxvirus subunit vaccines.
BACKGROUND: Vaccinia virus (VV) membrane proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic antibodies. Human antibody responses to these proteins after VV vaccination have not been well characterized. METHODS: Pre- and postvaccination (day 26-30) serum specimens from 80 VV vaccine recipients were examined for immunoglobulin G antibodies specific for B5, A33, A27, and L1 by enzyme-linked immunosorbent assay (ELISA). Responses were compared between vaccinia-naive and previously vaccinated (nonnaive) recipients and between nonnaive recipients of undiluted or 1 : 10 diluted vaccine. RESULTS: VV vaccination elicited anti-A33 and anti-A27 antibodies in nearly all vaccinia-naive subjects (100% and 93%, respectively). Preexisting antibodies were commonly detected in nonnaive subjects (for anti-B5, 68%; for anti-A33, 59%; for anti-A27, 38%; and for anti-L1, 10%). Anti-B5 antibodies were strongly boosted by undiluted vaccine (geometric mean titer [GMT], 151 vs. 1010 for pre- vs. postvaccination; P<.001), whereas anti-L1 antibody responses were less robust (detection rate, 31%; GMT, 75) in nonnaive subjects. Diluted vaccine elicited antibody responses that were similar to those elicited by undiluted vaccine. CONCLUSIONS: Vaccination with VV elicits long-lived specific antibody responses directed against VV membrane proteins that vary by previous vaccination status but not with respect to 10-fold dilution of vaccine. B5, A33, and A27 should be considered for inclusion in future human orthopoxvirus subunit vaccines.
Authors: Sharon E Frey; Robert B Couch; Carol O Tacket; John J Treanor; Mark Wolff; Frances K Newman; Robert L Atmar; Robert Edelman; Carrie M Nolan; Robert B Belshe Journal: N Engl J Med Date: 2002-03-28 Impact factor: 91.245
Authors: Sharon E Frey; Frances K Newman; John Cruz; W Brian Shelton; Janice M Tennant; Tamara Polach; Alan L Rothman; Jeffrey S Kennedy; Mark Wolff; Robert B Belshe; Francis A Ennis Journal: N Engl J Med Date: 2002-03-28 Impact factor: 91.245
Authors: Jeffrey S Halsell; James R Riddle; J Edwin Atwood; Pierce Gardner; Robert Shope; Gregory A Poland; Gregory C Gray; Stephen Ostroff; Robert E Eckart; Duane R Hospenthal; Roger L Gibson; John D Grabenstein; Mark K Arness; David N Tornberg Journal: JAMA Date: 2003-06-25 Impact factor: 56.272
Authors: Laura Evgin; Sergio A Acuna; Christiano Tanese de Souza; Monique Marguerie; Chantal G Lemay; Carolina S Ilkow; C Scott Findlay; Theresa Falls; Kelley A Parato; David Hanwell; Alyssa Goldstein; Roberto Lopez; Sandra Lafrance; Caroline J Breitbach; David Kirn; Harold Atkins; Rebecca C Auer; Joshua M Thurman; Gregory L Stahl; John D Lambris; John C Bell; J Andrea McCart Journal: Mol Ther Date: 2015-03-25 Impact factor: 11.454
Authors: Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir Journal: Clin Vaccine Immunol Date: 2009-07-15
Authors: Christiana N Fogg; Jeffrey L Americo; Patricia L Earl; Wolfgang Resch; Lydia Aldaz-Carroll; Roselyn J Eisenberg; Gary H Cohen; Bernard Moss Journal: J Virol Date: 2008-06-04 Impact factor: 5.103
Authors: Juan E Moyron-Quiroz; Megan M McCausland; Robin Kageyama; Alessandro Sette; Shane Crotty Journal: Vaccine Date: 2009-10-12 Impact factor: 3.641
Authors: Thomas Kaever; Michael H Matho; Xiangzhi Meng; Lindsay Crickard; Andrew Schlossman; Yan Xiang; Shane Crotty; Bjoern Peters; Dirk M Zajonc Journal: J Virol Date: 2016-04-14 Impact factor: 5.103
Authors: Mohammed Rafii-El-Idrissi Benhnia; Megan M McCausland; John Laudenslager; Steven W Granger; Sandra Rickert; Lilia Koriazova; Tomoyuki Tahara; Ralph T Kubo; Shinichiro Kato; Shane Crotty Journal: J Virol Date: 2009-09-30 Impact factor: 5.103